Cargando…

A Phase II Trial of Cabozantinib in Hormone Receptor‐Positive Breast Cancer with Bone Metastases

BACKGROUND: We assessed the antitumor activity of cabozantinib, a potent multireceptor oral tyrosine kinase inhibitor, in patients with hormone receptor‐positive breast cancer with bone metastases. PATIENTS AND METHODS: In this single‐arm multicenter phase II study, patients received an initial star...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Jing, Higgins, Michaela J., Tolaney, Sara M., Come, Steven E., Smith, Matthew R., Fornier, Monica, Mahmood, Umar, Baselga, Jose, Yeap, Beow Y., Chabner, Bruce A., Isakoff, Steven J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2020
Materias:	Breast Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7418363/ https://www.ncbi.nlm.nih.gov/pubmed/32463152 http://dx.doi.org/10.1634/theoncologist.2020-0127

Ejemplares similares

Prolonged recombinant pregnancy hormone use in BRCA1 and BRCA2 mutation carriers
por: Depypere, Herman, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in the Treatment of Breast Cancer Brain Metastases
por: Schlam, Ilana, et al.
Publicado: (2022)

A Multidisciplinary Breast Cancer Brain Metastases Clinic: The University of North Carolina Experience
por: McKee, Megan J., et al.
Publicado: (2016)

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone‐Only Metastases
por: Parkes, Amanda, et al.
Publicado: (2018)

Bone Metastases Detection in Patients with Breast Cancer: Does Bone Scintigraphy Add Information to PET/CT?
por: Cristo Santos, Joana, et al.
Publicado: (2023)

Treatment Outcome and Prognostic Factors for Patients with Bone-Only Metastases of Breast Cancer: A Single-Institution Retrospective Analysis
por: Niikura, Naoki, et al.
Publicado: (2011)

Adjuvant Olaparib for Germline BRCA Carriers With HER2-Negative Early Breast Cancer: Evidence and Controversies
por: Morganti, Stefania, et al.
Publicado: (2023)

Hormone Receptor Subtype in Ductal Carcinoma in Situ: Prognostic and Predictive Roles of the Progesterone Receptor
por: Hwang, Ki‐Tae, et al.
Publicado: (2021)

Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer
por: Barroso‐Sousa, Romualdo, et al.
Publicado: (2021)

Prognostic Factors for Overall Survival in Patients with Hormone Receptor‐Positive Advanced Breast Cancer: Analyses From PALOMA‐3
por: Rugo, Hope S., et al.
Publicado: (2021)

Real-World Evaluation of Disease Progression After CDK 4/6 Inhibitor Therapy in Patients With Hormone Receptor-Positive Metastatic Breast Cancer
por: West, Malinda T, et al.
Publicado: (2023)

Health‐Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor‐Positive, HER2‐Negative Advanced Breast Cancer After Endocrine Therapy
por: Kaufman, Peter A., et al.
Publicado: (2019)

Validation of Residual Proliferative Cancer Burden as a Predictor of Long‐Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor‐Positive/Human Epidermal Growth Receptor 2‐Negative Breast Cancer
por: Miglietta, Federica, et al.
Publicado: (2020)

Management of Abemaciclib‐Associated Adverse Events in Patients with Hormone Receptor‐Positive, Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Safety Analysis of MONARCH 2 and MONARCH 3
por: Rugo, Hope S., et al.
Publicado: (2020)

Long‐Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor‐Positive/Human Epidermal Growth Factor Receptor 2‐Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow‐Up
por: Finn, Richard S., et al.
Publicado: (2021)

Comparative Effectiveness of Palliative Chemotherapy in Metastatic Breast Cancer: A Real‐World Evidence Analysis
por: Feinberg, Bruce, et al.
Publicado: (2020)

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study
por: Litton, Jennifer K, et al.
Publicado: (2023)

Patient Characteristics Associated With Chemotherapy-Induced Peripheral Neuropathy Severity in a Phase II Clinical Trial: A Retrospective Analysis
por: Zhi, Wanqing Iris, et al.
Publicado: (2023)

Clinical outcomes and prognostic factors in patients with stage II-III breast cancer treated with neoadjuvant chemotherapy followed by surgery and postmastectomy radiation therapy in the modern treatment era
por: Nakajima, Naomi, et al.
Publicado: (2018)

Systemic Therapies Following Progression on First-line CDK4/6-inhibitor Treatment: Analysis of Real-world Data
por: Martin, James M, et al.
Publicado: (2022)

Overall Survival of Breast Cancer Patients With Locoregional Failures Involving Internal Mammary Nodes
por: Xu, Amy J., et al.
Publicado: (2019)

Is completion axillary lymph node dissection necessary in patients who are underrepresented in the ACOSOG Z0011 trial?
por: Gebhardt, Brian J., et al.
Publicado: (2018)

Pentoxifylline and vitamin E drug compliance after adjuvant breast radiation therapy
por: Famoso, Justin M., et al.
Publicado: (2017)

Evaluating the Age‐Based Recommendations for Long‐Term Follow‐Up in Breast Cancer
por: Witteveen, Annemieke, et al.
Publicado: (2020)

Duration of Chemotherapy-induced Nausea and Vomiting (CINV) as a Predictor of Recurrent CINV in Later Cycles
por: Navari, Rudolph, et al.
Publicado: (2022)

The Role of Race and Insurance Status in Access to Genetic Counseling and Testing Among High-Risk Breast Cancer Patients
por: Choi, Jihoon J, et al.
Publicado: (2022)

Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions
por: Schutte, Tim, et al.
Publicado: (2023)

Randomized Controlled Trial of a Home‐Based Walking Program to Reduce Moderate to Severe Aromatase Inhibitor‐Associated Arthralgia in Breast Cancer Survivors
por: Nyrop, Kirsten A., et al.
Publicado: (2017)

Predictors of radiation-induced acute skin toxicity in breast cancer at a single institution: Role of fractionation and treatment volume
por: Parekh, Arti, et al.
Publicado: (2017)

Tamoxifen Initiation After Ductal Carcinoma In Situ
por: Nichols, Hazel B., et al.
Publicado: (2016)

Koebner phenomenon: Consideration when choosing fractionation for breast irradiation
por: Wu, Cheng-Chia, et al.
Publicado: (2017)

A Comparison of Proposed Biosimilar LA-EP2006 and Reference Pegfilgrastim for the Prevention of Neutropenia in Patients With Early-Stage Breast Cancer Receiving Myelosuppressive Adjuvant or Neoadjuvant Chemotherapy: Pegfilgrastim Randomized Oncology (Supportive Care) Trial to Evaluate Comparative Treatment (PROTECT-2), a Phase III, Randomized, Double-Blind Trial
por: Blackwell, Kimberly, et al.
Publicado: (2016)

Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer
por: Tan, Weige, et al.
Publicado: (2019)

Quality of Life in Male Breast Cancer: Prospective Study of the International Male Breast Cancer Program (EORTC10085/TBCRC029/BIG2-07/NABCG)
por: Schröder, Carolien P, et al.
Publicado: (2023)

Patient-Reported Outcomes and Early Discontinuation in Aromatase Inhibitor-Treated Postmenopausal Women With Early Stage Breast Cancer
por: Kadakia, Kunal C., et al.
Publicado: (2016)

Physical Function and Physical Activity in Older Breast Cancer Survivors: 5-Year Follow-Up from the Climb Every Mountain Study
por: Lemij, Annelieke A, et al.
Publicado: (2023)

Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast Cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial
por: Di Cosimo, Serena, et al.
Publicado: (2022)

Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]‐Fluorothymidine Positron Emission Tomography Biomarker Study
por: Wesolowski, Robert, et al.
Publicado: (2020)

Breast Cancer and Pregnancy: Current Concepts in Diagnosis and Treatment
por: Litton, Jennifer K., et al.
Publicado: (2010)

Underuse of Anthracyclines in Women with HER-2(+) Advanced Breast Cancer
por: Montemurro, Filippo, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_29rqs2808r9mgsov9c4sf6t8r6